PRL‑8‑53
Phenyl-methyl-piperidinyl benzoate, 1970s, one published human memory trial.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Pharmacology
Contents
WHAT IS PRL-8-53?
Detailed overview
PRL-8-53 (methyl-3-(2-(benzyl(methyl)amino)ethyl)benzoate) was patented in 1972 (Dr. Nikolaus Hansl, Creighton University). A single 1978 double-blind placebo-controlled human trial (n=47, Hansl & Mehler, PMID 418433) described statistically significant verbal-memory improvement, enhanced long- and short-term recall, and modest motor-control gains; effects stronger in older and initially low-performing subjects. Anecdotally also used for language learning and vocabulary retention. Mechanism: cholinergic signal enhancement + dopamine potentiation + mild serotonin inhibition (per the original patent). High doses can produce convulsive effects, anxiety, insomnia. No follow-up trials since → thin database.
Mechanism
Cholinergic + dopaminergic modulation
Half-life
No published human data
Legal status
Investigational, not approved
Receptor profile
- Cholinergic signalingModerate
- Dopamine D2 receptorModerate
- Serotonin 5-HT2 receptorWeak
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Anxiety and restlessness reported at higher doses
- Insomnia and disturbed sleep (cholinergic-dopaminergic stimulation)
- Tremor and shakiness at higher doses
- Mild sweating in some users
- Risk of convulsive, seizure-type activity at high doses (per patent)
- Highly variable individual response, unpredictable effect profile
- Unknown long-term safety, no follow-up human data
Contraindications · 6
- Avoid during pregnancy and breastfeeding (no safety data)
- Avoid with seizure disorders or epilepsy (potential to lower seizure threshold)
- Caution with anxiety disorders or sleep disturbance
- Increased risk when combined with other dopaminergic or cholinergic agents
- Unapproved experimental compound sold as an uncontrolled research chemical, avoid high doses
- Limited human data, consider only cautiously at low doses under supervision
Related Nootropics
Same therapeutic category
FAQ
FAQ
PRL-8-53 is an older experimental compound, patented back in the 1970s, developed with the goal of improving memory. Only a single 1978 double-blind, placebo-controlled human trial ever studied it, and that trial makes up nearly everything we know about it. So while it's an interesting historical and research candidate in the memory space, there is still barely any reliable, repeated human evidence for how well it actually works.
Telegram
Have a question about PRL‑8‑53?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.